Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05807841

Clinical Impact of Intravascular Ultrasound-Based Artificial Intelligence Technologies (INNOVATE-PCI)

This study is a prospective, multicenter study in the real practice to validate the diagnostic performances and clinical impact of coronary angiography & intravascular ultrasound (IVUS)-based models developed by machine learning (ML).

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Soon Chun Hyang University Hospital Bucheon, Bucheon-si, South Korea

Loading trial locations.

About this study

The aim of the study is to evaluate the performances and prognostic impact of coronary angiography & IVUS-based algorithms for decision making and stent optimization in a multicenter, prospective cohort. Between January 2020 and June 2027, a total of 3,000 patients who performed coronary angiography (± FFR) and have at least one coronary stenosis requiring PCI (as culprit) will be enrolled from 16 centers in South Korea. In addition, the deferred lesions with visual estimated diameter stenosis of >30% will be evaluated as non-culprits. Brief study design is as depicted in the following figure.

Supervised ML algorithms include: 1) angiography- and IVUS-based algorithms for predicting FFR, 2) IVUS-based algorithm for plaque characterization, 3) IVUS-based algorithm for predicting stent expansion, and 4) post-stenting IVUS-based algorithm for predicting stent failure. In the prospective cohort, the performance of each model will be assessed. This registry trial composed of the treated (culprit) and the deferred (nonculprit) coronary lesions has two primary objectives as follow; 1) Primary objectives in treated (culprit) lesions is to see the impact of the integrated ML model on the development of culprit-related 2-year target vessel failure (TVF). 2) Primary objectives in deferred (nonculprit) lesions is to see the impact of the integrated ML model on the development of nonculprit-related 2-year TVF.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 19 years or older
  • Symptomatic angina patients with objective myocardial ischemia
  • Patients with at least one major epicardial coronary artery that requires stent implantation
  • Subject who signs with informed consent form

Patient exclusion Criteria:

  • ST-segment elevation MI at admission
  • Patients who underwent coronary artery bypass surgery or heart transplantation
  • Left ventricular ejection fraction <30%
  • Cardiogenic shock
  • Patients whose life expectancy <2 years
  • Woman who are breastfeeding, pregnant or planning to become pregnant during study
  • Patients in whom anti-platelets or heparin is contraindicated

Lesion exclusion Criteria:

  • Left main culprit lesion (angiographic diameter stenosis >50%)
  • Thrombus-containing lesion
  • In-stent restenosis
  • Side branch lesion
  • Chronic total occlusion
  • Small vessel with reference diameter <2.5mm
  • Coronary spasm despite administration of nitrate
  • Inability for imaging catheter to pass through tight stenosis, calcification, angulations
  • Poor image quality
  • Angiographically visible collateral vessels

Treatment and study plan

Percutaneous coronary intervention

Procedure

IVUS-guided stent implantation

Primary outcomes

  1. culprit-related TVF

    Time frame: 2 years after stent implantation

    composite of cardiac death, myocardial infarction (MI), stent thrombosis, and clinically-driven target vessel revascularization (TVR) at 2 years after SynergyTM implantation

  2. nonculprit-related TVF

    Time frame: 2 years after stent implantation

    composite of cardiac death, MI, and clinically-driven TVR at 2 years

Secondary outcomes

  1. each component of primary measures

    Time frame: 2 years after stent implantation

    each of cardiac death, non-fetal MI, ST and target vessel revascularization

  2. all cause death

    Time frame: 2 years after stent implantation

    all cause death

  3. repeat revascularization

    Time frame: 2 years after stent implantation

    repeat revascularization

  4. stroke

    Time frame: 2 years after stent implantation

    stroke

  5. bleeding

    Time frame: 2 years after stent implantation

    bleeding

Study contacts

Contact information is provided by the study sponsor or research team.

Seung-Whan Lee, MD

CONTACT

[email protected]

82-10-7398-9897

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Collaborators

  • Boston Scientific Corporation

Registry information

Official study title

Influence of Novel Intravascular Ultrasound-Based Artificial Intelligence Technologies on Event Reduction Following Percutaneous Coronary Intervention (INNOVATE-PCI)

Important dates

Study start
2020
Primary completion
2028
Study completion
2029
First posted
Apr 11, 2023
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.